All-Cause Mortality Associated with Tramadol Use: A Case-Crossover Study.

Abstract:

INTRODUCTION:Although the mortality risk associated with tramadol use in children has triggered the revision of tramadol drug labeling, the mortality risk in adults has not been thoroughly explored. OBJECTIVE:The objective of this study was to evaluate whether tramadol use is associated with mortality in various risk groups. METHODS:This was a case-crossover study addressing the period of 2004-2013, using data from the National Sample Cohort (National Health Insurance Service, South Korea). Patients who were prescribed tramadol at least once prior to their death were included. A 30-day hazard (case) period (with a 10-day washout period) was adopted and matched to three control periods. Logistic regression was used to estimate adjusted odds ratios (aORs) and their 95% confidence intervals (CIs). Adjustments were made for time-variant factors (co-medications, surgeries, and acute respiratory conditions). RESULTS:A total of 19,443 individuals were identified, with a small number of young individuals (n = 33, 0.2%). Tramadol use was associated with an increased mortality risk (aOR 1.77, 95% CI 1.67-1.87). Advanced age (> 75 years) (aOR 2.61, 95% CI 2.28-2.99) and renal (aOR 2.90, 95% CI 1.67-1.87) and hepatic (aOR 2.09, 95% CI 1.62-2.68) diseases were associated with the highest risks. CONCLUSION:Overall, there was an increased mortality risk associated with tramadol in the adult population. However, as residual confounding cannot be completely removed in large observational studies, this must be carefully interpreted in the decision-making regarding patient care.

journal_name

Drug Saf

journal_title

Drug safety

authors

Jeong S,Tchoe HJ,Li J,Shin JY

doi

10.1007/s40264-018-00786-y

subject

Has Abstract

pub_date

2019-06-01 00:00:00

pages

785-796

issue

6

eissn

0114-5916

issn

1179-1942

pii

10.1007/s40264-018-00786-y

journal_volume

42

pub_type

杂志文章
  • Methods for retrospective detection of drug safety signals and adverse events in electronic general practice records.

    abstract:BACKGROUND:Examination of clinical data routinely recorded in general practice provides significant opportunities for identifying and quantifying medicine-related adverse events not captured by spontaneous adverse reaction reporting systems. Robust pharmacovigilance methods for detecting and monitoring adverse events d...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/BF03261970

    authors: Tomlin A,Reith D,Dovey S,Tilyard M

    更新日期:2012-09-01 00:00:00

  • Epidemiology of adverse drug reactions in Europe: a review of recent observational studies.

    abstract::Adverse drug reactions (ADRs) cause considerable mortality and morbidity but no recent reviews are currently available for the European region. Therefore, we performed a review of all epidemiological studies quantifying ADRs in a European setting that were published between 1 January 2000 and 3 September 2014. Include...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-015-0281-0

    authors: Bouvy JC,De Bruin ML,Koopmanschap MA

    更新日期:2015-05-01 00:00:00

  • Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients.

    abstract:BACKGROUND AND OBJECTIVE:Rosuvastatin is a lipid-lowering drug, the newest of a class of drugs called HMG-CoA reductase inhibitors, or 'statins', launched in the UK in March 2003. Our objective was to monitor the post-marketing safety of this drug, prescribed in primary care in England, using prescription-event monitor...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200730020-00005

    authors: Kasliwal R,Wilton LV,Cornelius V,Aurich-Barrera B,Shakir SA

    更新日期:2007-01-01 00:00:00

  • Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis.

    abstract:BACKGROUND:An association between oral contraceptive (OC) use and venous thromboembolism (VTE) has long been recognized. However, no summary estimates of the increase in VTE risk associated with OC use have been available since 1995, and no meta-analyses have evaluated the VTE risk of new preparations containing drospi...

    journal_title:Drug safety

    pub_type: 杂志文章,meta分析,评审

    doi:10.2165/11598050-000000000-00000

    authors: Manzoli L,De Vito C,Marzuillo C,Boccia A,Villari P

    更新日期:2012-03-01 00:00:00

  • Risks and benefits of drugs used in the management of postoperative nausea and vomiting.

    abstract::Postoperative nausea and vomiting (PONV) is an age-old problem; more so since the blooming of ambulatory or day surgery centres within the last 2 decades. The aetiology of PONV is multifactorial. The incidence of PONV is usually higher in women and children than in men. PONV not only causes patient discomfort, anxiety...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199614030-00005

    authors: Sung YF

    更新日期:1996-03-01 00:00:00

  • Benefit-risk assessment of linezolid for serious gram-positive bacterial infections.

    abstract::Linezolid is an oxazolidinone, a new class of antibacterial with a unique mechanism of action, namely inhibition of the formation of a functional 70S initiation complex in the 50S bacterial ribosomal subunit. Linezolid is highly active against multidrug-resistant Gram-positive cocci, including meticillin-resistant Sta...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200831090-00004

    authors: Falagas ME,Vardakas KZ

    更新日期:2008-01-01 00:00:00

  • Assessment of Self-Administration of Romiplostim in Patients with Immune Thrombocytopenic Purpura after Receipt of Home Administration Training Materials: a Cross-Sectional Study.

    abstract:INTRODUCTION:Romiplostim is a subcutaneously administered thrombopoietin-receptor agonist approved in the European Union for self-administration (or administration by a caregiver) in selected adult patients with chronic primary immune thrombocytopenia refractory to other treatments. To mitigate the risk of medication e...

    journal_title:Drug safety

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s40264-018-0723-6

    authors: Schipperus M,Kaiafa G,Taylor L,Wetten S,Kreuzbauer G,Boshier A,Seesaghur A

    更新日期:2019-01-01 00:00:00

  • Cardiac effects of ebastine and other antihistamines in humans.

    abstract::The electrocardiographic effects of ebastine and its active metabolite, carebastine, have been studied alone and in relevant drug-interaction studies in various patient populations. The overall cardiac tolerability of ebastine is excellent. In ebastine dose-ranging studies in adults and children, there were no meaning...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199921001-00009

    authors: Moss AJ,Morganroth J

    更新日期:1999-01-01 00:00:00

  • Bias in benefit-risk appraisal in older products: the case of buflomedil for intermittent claudication.

    abstract::Benefit-risk assessment should be ongoing during the life cycle of a pharmaceutical agent. New products are subjected to rigorous registration laws and rules, which attempt to assure the availability and validity of evidence. For older products, bias in benefit-risk assessment is more likely, as a number of safeguards...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200932040-00003

    authors: De Backer TL,Vander Stichele RH,Van Bortel LM

    更新日期:2009-01-01 00:00:00

  • Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre.

    abstract:BACKGROUND:Rituximab is a monoclonal antibody approved for treating CD20-positive B-cell non-Hodgkin's lymphoma and rheumatoid arthritis but is used off-label for treating many autoimmune disorders, including multiple sclerosis (MS). Similarly to other monoclonal antibodies, the incidence of infusion-related reactions ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11585960-000000000-00000

    authors: Brown BA,Torabi M

    更新日期:2011-02-01 00:00:00

  • Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data.

    abstract:OBJECTIVE:Minocycline is an antibacterial drug used in the treatment of acne. Concern has been expressed over the possibility of severe adverse reactions to minocycline, including hepatitis. This study set out to identify and characterise reported cases of hepatotoxicity associated with the use of minocycline. METHODS...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200023040-00006

    authors: Lawrenson RA,Seaman HE,Sundström A,Williams TJ,Farmer RD

    更新日期:2000-10-01 00:00:00

  • A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience.

    abstract::Zopiclone is a cyclopyrrolone hypnosedative that is chemically unrelated to the benzodiazepines but nevertheless potentiates gamma-aminobutyric acid-mediated neuronal inhibition, and has demonstrated proven efficacy and good tolerability in the treatment of insomnia over 15 years of use. Zopiclone is indicated for sho...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199921060-00003

    authors: Hajak G

    更新日期:1999-12-01 00:00:00

  • Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.

    abstract:BACKGROUND:Although systems to collect information about suspected adverse drug reactions (ADRs) were established in many countries and by the WHO in the 1960s, few studies have examined reported ADRs related to national income. OBJECTIVE:The aim of the study was to characterize ADRs reported to the WHO-ADR database, ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/BF03262002

    authors: Aagaard L,Strandell J,Melskens L,Petersen PS,Holme Hansen E

    更新日期:2012-12-01 00:00:00

  • Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.

    abstract::Rhythm control in atrial fibrillation (AF) can be achieved using pharmacological therapy. Amiodarone is the most efficacious anti-arrhythmic agent; however, its use is limited due to an unfavourable safety profile, including pro-arrhythmia, thyroid, liver, skin and pulmonary complications. Dronedarone, which is struct...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-012-0012-8

    authors: Adlan AM,Lip GY

    更新日期:2013-02-01 00:00:00

  • A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.

    abstract:INTRODUCTION:An often key component to coordinating surveillance activities across distributed networks is the design and implementation of a common data model (CDM). The purpose of this study was to evaluate two drug safety surveillance CDMs from an ecosystem perspective to better understand how differences in CDMs an...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-015-0297-5

    authors: Xu Y,Zhou X,Suehs BT,Hartzema AG,Kahn MG,Moride Y,Sauer BC,Liu Q,Moll K,Pasquale MK,Nair VP,Bate A

    更新日期:2015-08-01 00:00:00

  • Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples.

    abstract:BACKGROUND:Several efforts are under way to develop and test methods for prospective drug safety monitoring using large, electronic claims databases. Prospective monitoring systems must incorporate signalling algorithms and techniques to mitigate confounding in order to minimize false positive and false negative signal...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11594770-000000000-00000

    authors: Wahl PM,Gagne JJ,Wasser TE,Eisenberg DF,Rodgers JK,Daniel GW,Wilson M,Schneeweiss S,Rassen JA,Patrick AR,Avorn J,Bohn RL

    更新日期:2012-05-01 00:00:00

  • In vitro models.

    abstract::The development of in vitro models is advancing rapidly, with the application of cell culture methods as an alternative to animals in toxicological screening; non-cellular systems are also being used. Any screening test, whether for detecting irritants, carcinogens or teratogens should be well validated against known ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199000051-00006

    authors: Anderson D

    更新日期:1990-01-01 00:00:00

  • Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.

    abstract::Blinatumomab is the first-and-only Food and Drug Administration (FDA)-approved cluster of differentiation (CD) 19-directed CD3 bispecific T-cell engager (BiTE®) immunotherapy. It is currently FDA approved for the treatment of adults and children with Philadelphia chromosome-positive (Ph+) and Philadelphia chromosome-n...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-018-0760-1

    authors: Stein A,Franklin JL,Chia VM,Arrindell D,Kormany W,Wright J,Parson M,Amouzadeh HR,Choudhry J,Joseph G

    更新日期:2019-05-01 00:00:00

  • A Novel Approach to Visualize Risk Minimization Effectiveness: Peeping at the 2012 UK Proton Pump Inhibitor Label Change Using a Rapid Cycle Analysis Tool.

    abstract:INTRODUCTION:Evaluation of risk minimization (RM) actions is an emerging area of regulatory science, often without tools to rapidly and systematically assess their effectiveness. PURPOSE:The aim of this study was to evaluate whether chronographs, typically used for rapid signal detection in observational longitudinal ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-019-00853-y

    authors: Sobel RE,Blackwell W,Fram DM,Bate A

    更新日期:2019-11-01 00:00:00

  • Predictors and timing of adverse experiences during trandsdermal nicotine therapy.

    abstract:OBJECTIVES:Difficulty sleeping is a recognised tobacco withdrawal symptom, but sleep problems, like application site reactions, are commonly reported as adverse reactions to transdermal nicotine therapy. However, no studies have examined potential predictive factors associated with the occurrence of expected adverse ex...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-199920060-00007

    authors: Gourlay SG,Forbes A,Marriner T,McNeil JJ

    更新日期:1999-06-01 00:00:00

  • Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England.

    abstract:OBJECTIVES:A prescription event monitoring (PEM) postmarketing surveillance study was carried out to examine the safety of zafirlukast as used in general practice in England. METHODS:Exposure data were obtained from the first National Health Service (NHS) prescription dispensed for patients whose prescription details ...

    journal_title:Drug safety

    pub_type: 临床试验,杂志文章

    doi:10.2165/00002018-200730050-00005

    authors: Twaites BR,Wilton LV,Shakir SA

    更新日期:2007-01-01 00:00:00

  • Impact on Drug Safety of Variation in Adherence: The Need for Routinely Reporting Measures of Dose Intensity in Medication Safety Studies Using Electronic Health Data.

    abstract::Randomized controlled trials always report the dose assessed and usually include a measure of adherence. By comparison, observational studies assessing medication safety often fail to report the dose used and rarely report any measure of adherence to therapy. This limits the ability to control for differences in doses...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-015-0347-z

    authors: Roughead EE,Pratt NL

    更新日期:2015-12-01 00:00:00

  • Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database.

    abstract:BACKGROUND:Following reports of sudden death in patients taking medication to treat attention-deficit hyperactivity disorder (ADHD), this study aimed to identify cases of death in patients prescribed stimulants and atomoxetine and to determine any association between these and sudden death. METHOD:The UK General Pract...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11317630-000000000-00000

    authors: McCarthy S,Cranswick N,Potts L,Taylor E,Wong IC

    更新日期:2009-01-01 00:00:00

  • How do we best detect toxic effects of drugs taken during pregnancy? A EuroMap paper.

    abstract::It is a major clinical and public health problem that there is no clear strategy as to how we best make use of information obtained when pregnant women take drugs. For this reason, some pregnant women are not treated as they should be and some are given drugs they should not use. We suggest a monitoring system that co...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200225010-00003

    authors: Olsen J,Czeizel A,Sørensen HT,Nielsen GL,de Jong van den Berg LT,Irgens LM,Olesen C,Pedersen L,Larsen H,Lie RT,de Vries CS,Bergman U

    更新日期:2002-01-01 00:00:00

  • Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest.

    abstract::The entire drug safety enterprise has a need to search, retrieve, evaluate, and synthesize scientific evidence more efficiently. This discovery and synthesis process would be greatly accelerated through access to a common framework that brings all relevant information sources together within a standardized structure. ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-014-0189-0

    authors: Boyce RD,Ryan PB,Norén GN,Schuemie MJ,Reich C,Duke J,Tatonetti NP,Trifirò G,Harpaz R,Overhage JM,Hartzema AG,Khayter M,Voss EA,Lambert CG,Huser V,Dumontier M

    更新日期:2014-08-01 00:00:00

  • Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France.

    abstract:BACKGROUND:Automated disproportionality analysis of spontaneous reporting is increasingly used routinely. It can theoretically be influenced by a competition bias for signal detection owing to the presence of reports related to well-established drug-event associations. OBJECTIVE:The aim of the study was to explore the...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/BF03261981

    authors: Pariente A,Avillach P,Salvo F,Thiessard F,Miremont-Salamé G,Fourrier-Reglat A,Haramburu F,Bégaud B,Moore N,Association Française des Centres Régionaux de Pharmacovigilance (CRPV).

    更新日期:2012-10-01 00:00:00

  • A risk-benefit assessment of therapies for Lennox-Gastaut syndrome.

    abstract::The treatment of Lennox-Gastaut syndrome has been improved for some patients by the introduction of adjunctive therapy with newer anticonvulsants such as lamotrigine and topiramate and the availability of vagal nerve stimulation and the re-emergence of the use of the ketogenic diet in recent years. The place of standa...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200022060-00005

    authors: Schmidt D,Bourgeois B

    更新日期:2000-06-01 00:00:00

  • Impact of electrocardiographic data quality on moxifloxacin response in thorough QT/QTc studies.

    abstract:BACKGROUND:Thorough QT studies are typically conducted for drugs with systemic bioavailability and include a positive control, typically moxifloxacin, with a well-described QTc effect. OBJECTIVE:This study tested two hypotheses: that (i) re-measuring the QT intervals based on electrocardiogram (ECG) pattern similarity...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-014-0142-2

    authors: Johannesen L,Garnett C,Malik M

    更新日期:2014-03-01 00:00:00

  • Using MedDRA: implications for risk management.

    abstract::The introduction of MedDRA, the Medical Dictionary for Regulatory Activities, as a standardised terminology may have a major impact on the performance of risk management. Thus, MedDRA is likely to have an important effect on the analysis of clinical trial safety data. Review of the most commonly used terms in clinical...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200427080-00010

    authors: Brown EG

    更新日期:2004-01-01 00:00:00

  • Variation in choice of study design: findings from the Epidemiology Design Decision Inventory and Evaluation (EDDIE) survey.

    abstract:BACKGROUND:Researchers using observational data to understand drug effects must make a number of analytic design choices that suit the characteristics of the data and the subject of the study. Review of the published literature suggests that there is a lack of consistency even when addressing the same research question...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-013-0103-1

    authors: Stang PE,Ryan PB,Overhage JM,Schuemie MJ,Hartzema AG,Welebob E

    更新日期:2013-10-01 00:00:00